康柏西普3+PRN和3+Q3M玻璃体腔注射方案治疗湿性年龄相关性黄斑变性的临床效果

Clinical effects of conbercept 3+PRN and 3+Q3M intravitreal injection in the treatment of wet age-related macular degeneration

目的比较康柏西普3+PRN(1次/月,1针/次,连续3针后,延长期按需给药)和3+Q3M(1次/月,1针/次,连续3针后,延长期注射1次/3个月)玻璃体腔注射方案治疗湿性年龄相关性黄斑变性的临床效果。方法选取我院2017年1月至2021年6月收治的97例湿性年龄相关性黄斑变性患者为研究对象,随机将其分为3+PRN组(48例,康柏西普3+PRN玻璃体腔注射)和3+Q3M组(49例,康柏西普3+Q3M玻璃体腔注射)。比较两组的治疗效果。结果两组的治疗总有效率比较,差异无统计学意义(P>0.05)。3+Q3M组的注射总次数多于3+PRN组,1年内疾病复发率低于3+PRN组,差异具有统计学意义(P<0.05);两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。最后1次术后第2天(T5)至最后1次术后30 d(T6),3+Q3M组的裸眼视力(UCVA)、最佳矫正视力(BCVA)高于3+PRN组,黄斑中心凹视网膜厚度(CRT)、中心区视网膜容积(CSV)低于3+PRN组,差异具有统计学意义(P<0.05)。结论康柏西普3+PRN和3+Q3M玻璃体腔注射方案治疗湿性年龄相关性黄斑变性患者均可取得显著效果,但3+Q3M方案较3+PRN方案具有更佳的视力改善和预后改善作用,且远期疗效更佳,值得临床推广和应用。

Objective To compare the clinical effects of conbercept 3+PRN(1 time/month,1 needle/time,extended period on-demand administration after 3 consecutive needles)and 3+Q3M(1 time/month,1 needle/time,extended period injection 1 time/3 months after 3 consecutive needles)intravitreal injection in the treatment of wet age-related macular degeneration.Methods A total of 97 patients with wet age-related macular degeneration admitted in our hospital from January 2017 to June 2021 were selected as the research objects,and the patients were randomly divided into 3+PRN group(48 cases,conbercept 3+PRN intravitreal injection)and 3+Q3M group(49 cases,conbercept 3+Q3M intravitreal injection).The therapeutic effects of the two groups were compared.Results There was no significant difference in the total effective rate between the two groups(P>0.05).The total number of injections in the 3+Q3M group was more than that in the 3+PRN group,and the recurrence rate within 1 year was lower than that in the 3+PRN group,and the differences were statistically significant(P<0.05);there was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).From the 2nd day after the last operation(T5)to the 30th day after the last operation(T6),the uncorrected visual acuity(UCVA)and best corrected visual acuity(BCVA)in the 3+Q3M group were higher than those in the 3+PRN group,and the central retinal thickness(CRT)and central subfield volume(CSV)were lower than those in the 3+PRN group,and the differences were statistically significant(P<0.05).Conclusion Conbercept 3+PRN and 3+Q3M intravitreal injection regimens can achieve statistical results in the treatment of patients with wet age-related macular degeneration,but 3+Q3M regimen has better visual acuity improvement and prognosis improvement than 3+PRN regimen,with better long-term efficacy,which is worthy of clinical promotion and application.